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ABSTRACT 
Objective: The main objective of the proposed study was to develop a sensitive, rapid and stability indicating reverse phase UV-UPLC method for 
the quantitative determination of potential impurities in carvedilol.  
Methods: The chromatographic separations were achieved on waters Acquity UPLC BEH C18 column (100 mm length 2.1 mm ID with 1.7 µm 
particle size, Waters corporation, MA, USA). Mobile phase A consisted, 0.04% trifluroacetic acid in water and mobile phase B consisted as 0.04% 
trifluroacetic acid in acetonitrile with a gradient programme (Tmin A:B) T090:10, T465:35, T740:60, T1020:80, T10.1 90:10. The column temperature 
was maintained at 60 °C and the detection was carried out at 240 nm. The flow rate was set to 0.5 mL/min. 
Results: Efficient chromatographic separation was achieved on UPLC BEH C18 stationary phase in gradient mode using simple mobile phase. In 
forced degradation study, major degradation of the drug substance was found to occur under oxidative stress conditions to form carvedilol 
hydroxylamine. The method was validated according to ICH guidelines with respect to specificity, precision, linearity and accuracy. Regression 
analysis showed the correlation coefficient value greater than 0.999 for carvedilol and its five impurities. Detection limit of impurities was in the 
range of 0.002–0.004% indicating the high sensitivity of the newly developed method. Accuracy of the method was established based on the 
recovery obtained between 96.7% and 108.1% for all impurities. 
Conclusion: A new, rapid and highly efficient UPLC method was developed, which separates all impurities and degradation products of carvedilol. 
The method has been validated in order to ascertain the suitability and stability indicating power of the method. 




ethyl)amino)-2-propanol (Figure 1), is nonselective β-blocking agent 
with vasodilatation properties attributed mainly to its blocking 
activity at α1-receptors. Carvedilol has much greater antioxidant 
activity than other commonly used blockers. It has been prescribed 
as an antihypertensive agent, an antiangina agent [1-4], and for 
treatment of congestive heart failure (CHF) [5].  
Carvedilol is both a beta blocker (β1, β2) and an alpha blocker (α1), 
Norepinephrine stimulates the nerves that control the muscles of the 
heart by binding to the β1- and β2-adrenergic receptors. Carvedilol 
blocks the binding to those receptors [6] which both slows the heart 
rhythm and reduces the force of the heart's pumping. This lowers 
blood pressure thus reducing the workload of the heart, which is 
particularly beneficial in heart failure patients. Norepinephrine also 
binds to the α1-adrenergic receptors on blood vessels, causing them 
to constrict and raise blood pressure. Carvedilol blocks this binding 
to the α1-adrenergic receptors too [7], which also lower blood 
pressure. Carvedilol is a racemic compound and the stereoselectivity 
of the carvedilol enantiomers was established. The effects of the 
levorotatory S(-)-enantiomer are vasodilatation and beta blocking. 
The R(+)-enantiomer is a pure vasodilatation agent. HPLC methods 
for the determination of carvedilol related impurities were reported 
in USP, EP and BP [8-9]. Different analytical methods have been 
reported for the determination of carvedilol, its metabolites and 
enantiomers including liquid chromatography, liquid 
chromatography-mass spectrometry-mass spectrometry 
(HPLC/MS/MS), and electrophoresis [10-15].  
Ultra Performance Liquid Chromatography (UPLC) is a relatively 
new technique giving new possibilities in liquid chromatography, 
especially concerning the decrease of time and solvent consumption. 
The separation on UPLC is performed under very high pressures (up 
to 100MPa is possible in UPLC system), but it has no negative 




Molecular weight = 406.49, Molecular formula = C24H26N2O4 
Fig. 1: Structure of Carvedilol. 
 
Separation efficiency remains maintained or is even improved 
comparing to the conventional system using 5 µm particle packed 
analytical columns. As it is very well known from Van Deemter 
equations, the efficiency of the chromatographic process is 
proportional to particle size decrease. This model describing band 
broadening, which explains the relationship between the height 
equivalent of the theoretical plate (HETP) and linear velocity, one of 
the terms (path dependent term), is dependent on a diameter of 
particle packed into the analytical column [16].  
Detailed literature study shown that there are no UPLC methods 
reported for the quantification of carvedilol impurities. In the 
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present study, we report the development and validation of a new 
UPLC method, enabling the determination of carvedilol potential 
impurities and other degradation products. 
MATERIALS AND METHODS 
Reagents and Chemicals 
Samples of carvedilol and standards of Imp-1, Imp-2, Imp-3, Imp-4 
and Imp-5 (Table 1) were received from Deepta laboratories, 
Mysore, India. HPLC grade methanol and acetonitrile were 
purchased from Rankem, Mumbai, India. Deionized water was 
prepared using a Milli-Q plus water purification system from 
Millipore (Bedford, MA, USA). AR grade Trifluoro acetic acid 
purchased from Qualigens Fine Chemicals, Mumbai, India. Analytical 
reagent grade potassium dihydrogen phosphate, ammonium acetate, 
sodium hydroxide, hydrochloric acid, hydrogen peroxide and ortho 
phosphoric acid were purchased from Merck India Limited 
(Mumbai, India). 
Instruments 
Samples were analysed on Agilent 1290 Infinity UPLC equipped with 
PDA detector (Agilent technologies, CA, USA). The MS studies were 
performed on Agilent 1290 Infinity UPLC coupled with single 
quadrupole 6140 MS and chemstation software (Agilent 
technologies, CA, USA) using multi mode source electrospray 
ionization (ESI) and atmospheric pressure chemical ionization 
(APCI). The typical source conditions were; gas: nitrogen, drying gas 
flow: 10 L/min, nebuliser pressure: 30psig, drying gas temperature: 
250 °C, Vaporiser temperature: 200 °C, Capillary voltage: 3500V, 
corono current: 4.0 µA, charging voltage: 2000 V. 1H spectra were 
recorded using a Bruker 400 MHz spectrometer (Bruker, Fallanden, 
Switzerland) equipped with a 5 mm BBO probe and a z-gradient 
shim system. The 1H spectra were recorded with 1s pulse repetition 
time using 30° flip angle. Samples were dissolved in dimethyl 
sulphoxide-d6. The 1H chemical shift values were reported on the δ 
scale in ppm relative to DMSO-d6 (2.50 ppm).  
Chromatographic conditions 
The chromatographic separations were achieved on waters Acquity 
UPLC BEH C18 column (100 mm length × 2.1 mm ID with 1.7 µm 
particle size, Waters corporation, MA, USA). Mobile phase A 
consisted, 0.04% trifluroacetic acid in water and Mobile phase B 
consisted as 0.04% trifluroacetic acid in acetonitrile with a gradient 
programme (TminA:B) T090:10, T465:35, T740:60, T1020:80, T10.1 
90:10 with a post-run time of 2.5 min. The column temperature was 
maintained at 60 °C and the detection was carried out at 240 nm. The 
flow rate was set to 0.5 mL/min. The test concentration was about 
100 µg/mL and the injection volume was 3 µL. A degassed mixture 
of mobile phase A and mobile phase B in the ratio of 70:30 (v/v) was 
used as diluent during the standard and test samples preparations. 
Sample preparation for forced degradation studies 
Stress study is a complementary part of stability testing wherein 
influence of environmental factors like pH, temperature, humidity, 
oxygen and light are evaluated on a drug substance and products. 
Stress testing of the drug substance was performed as per ICH 
guidelines Q1 (R2) and it can help to identify the likely degradation 
products, which can in turn help to establish the degradation 
pathways, the intrinsic stability of the molecule and specificity of the 
proposed method. Specificity is the ability of the method to measure 
the analyte response in the presence of its potential impurities. Acid 
hydrolysis was performed in 0.01N, 0.1N, and 0.5N HCl at 70 °C for 2 
days. The study in basic solution was carried out in 0.01N, 0.1N, 
0.5N, 1N NaOH at 70 °C for 7 days. For study in neutral solution, the 
drug dissolved in water and was kept at 70 °C for 7 days. Oxidation 
studies were carried out at ambient temperature in 1%, 5%, 10% 
and 20% hydrogen peroxide for 3days. Samples were withdrawn at 
appropriate times and subjected to LC analysis after suitable dilution 
(100 µg/mL) to evaluate the suitability of the proposed method to 
separate carvedilol from its degradation products. The excess of acid 
or base in volumetric flasks were neutralized and made up to the 
volume with diluent. Corresponding blank solutions were prepared 
following the sample procedure without carvedilol sample. Thermal 
degradation was done at 105 °C for 72 h on the solid sample. 
Photodegradation studies were carried out according to option 2 of 
Q1B in ICH guidelines. Photolytic degradation was performed by 
keeping 250 mg of each sample in two separate losses on drying 
(LOD) bottles in a photo stability chamber model TP 0000090G 
(Thermo Lab equipments Pvt. Ltd., Mumbai, India). One bottle was 
covered with lid and then with aluminium foil (dark control) 
whereas another bottle (photolytic exposed sample) was covered 
with lid to get a minimum exposure of 1.2 million lux hours for light 
and 200 Wh/m2 for ultraviolet region. A 0.1 mg/mL samples were 
prepared for thermal degradation and photolytic degradation 
samples. 
Preparation of stock solutions for method validation 
A test preparation of 100 µg/mL of carvedilol API sample was 
prepared by dissolving in diluent. A stock solution of impurities was 
prepared by dissolving 5 mg each of Imp-1, Imp-2, Imp-3, Imp-4, 
Imp-5, and 5 mg of carvedilol in diluent and made up to 50 mL with 
diluent. Transferred 1 mL of each individual stock solution into a 
100 mL volumetric flask and made up to volume with diluent. From 
this stock solution, standard solution of 0.10 µg/mL of each impurity 
and 0.10 µg/mL of carvedilol was prepared.  
RESULTS AND DISCUSSION 
Method development  
The main objective of the UPLC method development was to achieve 
efficient separation of impurities, degradation products generated 
during stress studies and a short run time of the method. All 
impurities are listed in Table-1 and named based on their elution 
pattern. Carvedilol has a basic in nature due to the presence of an 
amino group with a pKa value of 7.97. However other commonly 
used β-blockers has pKa value around 9.5 and the difference is 
attributed primarily to the inductive effect of the β-O-atom, which 
lowers the basicity of the amino group. As a LC method development 
rule, one should work within ±1.5 pH unit of the pKa value of the 
analyte for good pH control of the mobile phase. This assures that 
the analytes are either 100% ionized or 100% non-ionized and 
should help control run-run reproducibility. On consideration of the 
above points, an acidic mobile phase was chosen as a part of initial 
method development screening of carvedilol and its potential 
impurities. Carvedilol is a hydrophobic drug, almost insoluble in 
aqueous media and freely soluble in organic solvents, for example 
methanol and acetonitrile.  
For the initial experiments, a BEH C18 column with 100 mm length × 
2.1 mm ID column and 1.7 µm particle size was chosen. The oven 
temperature, detector wavelength and injection volume used were 
25 °C, 240 nm and 5 µl were used. The optimal absorption 
wavelength for detection of the compounds was chosen especially 
with regard to absorption spectra of carvedilol impurities. Carvedilol 
and its impurities give higher detector response at 240 nm, 
therefore the final absorption wavelength for detection was chosen 
at 240 nm. UV spectra of carvedilol have been depicted in Figure 2. 
Many experiments were conducted to get a baseline resolution 
between carvedilol and impurities. The resolution between imp-1, 
imp-2 and carvedilol was poor when different UPLC columns viz; 
RP18, HSS and phenyl were used in different mobile phases 
containing phosphate, acetate and TFA along with acetonitrile, 
methanol, with pH ranging from 2 to 6. The optimum pH of the 
mobile phase selected was around in between 2.0 to 2.5 because at 
pH values higher than 3.0, a somewhat larger peak tailing and lack of 
resolution between impurities was resulted. And also at pH 2.5 for 
the mobile phase, carvedilol completely in ionized form and 
obtained a better peak shape. Use of C18 column with a 100 mm 
length × 2.1 mm ID column and 1.7 µm particle size, use of TFA as 
mobile phase modifier and acetonitrile–water mixture as mobile 
phase-B and column temperature at 60 °C was significant in 
achieving the desired resolution of carvedilol and its impurities. 
Studies on the effect of column temperature shown that a better 
baseline and low back pressure were observed at the higher 
temperature without affecting much resolution between impurities. 
After several trials for gradient profile, chromatographic conditions 
were finalized as described under section chromatographic conditions.  
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Fig. 2: UV absorption spectra of Carvedilol 
 
Results of forced degradation 
Carvedilol was found to be stable under stress conditions such as 
thermal, photolytic and basic hydrolysis conditions. According to a 
literature, a decomposition product as well as process related 
impurity 4-hydroxycarbozole was formed after carvedilol exposed 
to daylight almost 100 days. However, decomposition product was 
below 0.1% after keeping the sample such a long time. The newly 
developed method was able to separate this impurity from 
carvedilol and other known impurities. Significant degradation of 
the drug substance was observed under oxidative stress conditions 
leads to a major degradation product at RRT 0.93. LC/MS analysis 
was carried out to identify this degradation product of carvedilol 
using Agilent 6140 single quadrupole mass spectrometer. The 
degradation product shows the masses of 422 which is 16 higher 
masses than carvedilol mass 406. The impurity formed at RRT 0.93 
was identified as shown in Table 1 and was formed due to the 
oxidation of secondary amine to hydroxyl amine after 
rearrangement of the N-oxide formation [17].  
Acid hydrolysis stressed sample shown multiple peaks in the 
chromatogram. The LC/MS analysis has shown that mass spectra of 
the each peak having chlorine pattern indicating that the 
degradation products formed may be due to the side reaction 
between and carvedilol and hydrochloric acid.  
Hence no further studies have been carried out to identify these 
degradation products. Chromatograms of forced degradation study 
have been depicted in Figure 4 and the summary report of forced 
degradation studies are depicted in Table 3. 
Degradation studies and peak purity test results derived from PDA 
detector and LC/MS confirmed that the carvedilol peak was 
homogenous and pure in all the stress samples. The developed UPLC 
method was found to be specific in the presence of Imp-1, Imp-2, 
Imp-3, Imp-4, Imp-5 and their degradation products confirmed the 
stability indicating power of the newly developed method. 
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propyl]-N-[2-(2-methoxyphenoxy) ethyl]  
hydroxylamine. 
- Oxidative degradation 
impurity 
 
Table 2: Method validation summary report 
Parameter Imp-1 Imp-2 Carvedilol  Imp-3  Imp-4  Imp-5 
System suitability       
 RT 4.30 4.50 4.86 6.26 6.64 7.30 
 RRT 0.88 0.93 1.00 1.29 1.37 1.50 
 Rs - 3.42 6.28 23.79 7.76 11.66 
 N 57469 157825 79144 267067 300172 208317 
 T 1.05 1.06 1.08 1.29 1.06 1.10 
Linearity       
 r 0.9995 0.9973 0.9978 0.9994 0.9995 0.9992 
 Slope  74.88 20.11 32.144 29.232 38.52 55.093 
 Intercept -0.1713 -0.0574 0.0198 -0.0397 0.0009 0.0164 
Detection limit (%) 0.002 0.004 0.002 0.002 0.002 0.002 
Quantitation limit (%) 0.006 0.01 0.006 0.006 0.006 0.006 
Precision (QL) 
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 Intermediate precision  
(inter day) 













Accuracy at QL level (n 3)       
 Amount added (%) 0.0060 0.0100 - 0.0060 0.0060 0.0060 
 Amount recovered (%) 0.0062 0.0101  0.0062 0.0064 0.0058 
 % Recovery 103.3 101.0  103.3 106.7 96.7 
Accuracy at 80% level (n 3)       
 Amount added (%) 0.08 0.08 - 0.08 0.08 0.08 
 Amount recovered (%) 0.0870 0.0823  0.0874 0.0840 0.0822 
 % Recovery  105.8 102.8  106.2 105.0 102.7 
Accuracy at 100% level (n 3) 
Amount added (%) 
Amount recovered (%) 























Accuracy at 120% level (n 3)       
 Amount added (%) 0.12 0.12 - 0.12 0.12 0.12 
 Amount recovered (%) 0.1213 0.1218  0.1278 0.1308 0.1321 
 % Recovery  101.1 101.5  106.5 108.1 104.1 
n, number of determinations; RT, retention time; RRT, relative retention time; Rs, USP resolution; N, number of theoretical plates; T, USP tailing 
factor; r, correlation coefficient. 
 
Table 3: Summary report of forced degradation study 
Stress condition Time (h) % Assay of active substance % of degradation products Mass balance* (%) 
Acid Hydrolysis (0.5N HCl) 48 85.1 13.7 98.8 
Basic Hydrolysis (1N NaOH) 168 99.6 - 99.6 
Oxidation (20% H2O2) 72 75.6 22.7 98.3 
Dry Heat (105 °C) 72 99.7 - 99.7 
Wet Heat (70 °C) 168 99.2 - 99.2 
UV (254 nm) 72 99.4 - 99.4 
*It is the summation of assay of active substance and % of degradation products 
Sajan et al. 




Table 4: Mass and 1H NMR chemical shift values 
Name of 
impurity 
Mass value (m/z) 
(M+H) 
1H NMR chemical shift values, δ in ppm, 
 
Carvedilol 407 8.2 (d, 1H, ArH), 7.45 (d, 1H, ArH), 7.3 (m, 2H, ArH), 7.1 (m, 2H, ArH), 6.8-7.0 (m, 4H, ArH), 6.67 (d, 1H, 
ArH), 4.1-4.3 (m, 5H, -O-CH2- and -CH), 3.71 (s, 3H, -CH3), 2.9-3.2 (m, 4H, -CH2). 
IMP-1 184 8.15 (d, 1H, ArH), 7.4 (d, 1H, ArH), 7.35 (t, 2H, ArH), 7.15 (m, 2H, ArH), 6.9 (d, 1H, ArH), 6.55 (d, 1H, ArH). 
IMP-2 630 8.26 (d, 1H, ArH), 7.61 (d, 1H, ArH), 7.33 (m, 2H, ArH), 7.23 (d, 1H, ArH), 7.15 (t, 1H, ArH), 6.82-6.98 (m, 
8H, ArH), 6.72 (d, 1H, ArH), 3.91-4.50 (m, 10H, -CH2 and -CH), 3.70 (d, 6H, -CH3), 2.95 (m, 2H, -CH2), 2.95 
(m, 2H, -CH2), 2.63 (m, 2H, -CH2). 
IMP-3 497 8.19 (d, 1H, ArH), 7.4 (m, 3H, ArH), 7.27 (m, 5H, ArH), 7.06 (m, 2H, ArH), 6.89 (d, 1H, ArH), 6.82 (t, 1H, 
ArH), 6.69 (t, 1H, ArH), 6.61 (m, 2H, ArH), 3.95-4.24 (m, 5H, -O-CH2 and -CH), 3.82 (q, 2H, -CH2), 3.65 (s, 
3H, -CH3), 2.75-2.93 (m, 4H, -CH2-). 
IMP-4 646 8.24 (d, 2H, ArH), 7.41 (d, 2H, ArH), 7.28 (m, 2H, ArH), 7.21 (m, 2H, ArH), 7.06 (m, 4H, ArH), 6.85 (m, 2H, 
ArH), 6.57 (m, 4H, ArH), 3.9-4.2 (m, 8H, -O-CH2 and CH-), 3.59 (d, 3H, -CH3), 2.8-3.06 (m, 6H, -CH2). 
IMP-5 423 8.25 (d, 2H, ArH), 7.45 (d, 2H, ArH),), 7.28 (m, 4H, ArH), 7.05 (m, 4H, ArH), 6.7 (d, 2H, ArH), 4.4-4.6 (m, 5H, 
-CH2- and CH. 
 
 
Fig. 3: Chromatogram of carvedilol spiked with impurities. 
Structural Elucidation 
Carvedilol and its all impurities (Imp-1, Imp-2, Imp-3, Imp-4, and 
Imp-5) were characterized with the help of MS and NMR 
spectroscopic techniques. The mass and 1H NMR chemical shift 
values of these impurities are presented in Table 4. 
Method validation 
The newly developed method was validated for sensitivity, linearity, 
precision and accuracy, robustness and system suitability according 
to ICH guidelines [18]. Validation study was carried out for Imp-1, 
Imp-2, Imp-3, Imp-4 and Imp-5. The system suitability and 
selectivity were checked by injecting 100 µg/mL of carvedilol 
solution containing 0.1µg/mL of all impurities monitored 
throughout the validation. Method validation results are 
summarized in Table 2.  
Limit of detection (LOD) and limit of quantitation (LOQ) 
The limit of detection and limit of quantitation were determined for 
carvedilol and for each of the related substances as per ICH Q2R1 
guideline. The LOD and LOQ for Imp-1, Imp-2, Imp-3, Imp-4 and 
Imp-5 and carvedilol were estimated at a signal-to-noise ratio of 3:1 
and 10:1, respectively by injecting a series of diluted solutions with 
known concentration. The limit of detection and the limit of 
quantitation for imp-1, imp-3, imp-4, imp-5 and carvedilol were 
about 0.002% and 0.006% and for imp-2 was about 0.004% and 
0.01% of analyte concentration i. e. 100 µg/mL respectively. The 
calculated LOQ concentrations of all the components were verified 
for precision by injecting six individual preparations of Imp-1, Imp-
2, Imp-3, Imp-4, Imp-5, and carvedilol. The RSD of LOQ precision 
was in the range of 1.6–4.1 %.  
Linearity and range 
The linearity of an analytical procedure is its ability (within a given 
range) to obtain test results, which are directly proportional to the 
concentration of the analyte in the sample. A linearity test solution 
for related substance method was prepared by diluting the impurity 
stock solution to the required concentrations.  
The solutions were prepared at six concentration levels from LOQ to 
150% of the permitted maximum level of the impurity (i. e. LOQ, 0.02 
µg/mL, 0.05 µg/mL 0.08 µg/mL, 0.10 µg/mL, 0.12 µg/mL, 0.15 µg/mL) 
was subjected to linear regression analysis with the least squares 
method. Calibration equation obtained from regression analysis was 
used to calculate the corresponding predicted responses.  
The residuals and sum of the residual squares were calculated from 
the predicted responses. The correlation coefficient obtained was 
greater than 0.99 for all impurities. The result showed an excellent 
correlation between the peak and concentration of all impurities. 
The range of the method was from LOQ to 0.15 µg/mL of the analyte 
concentration (100 µg /mL). 
Precision  
Precision of the method was studied for method precision and 
intermediate precision. Method precision was checked by injecting 
six individual preparations of (100 µg/mL) carvedilol spiked with 
0.1µg/mL of each impurity. In the intermediate precision study, the 
similar procedure of method precision was carried out by a different 
day. % RSD of areas of each impurity was within 5.0, confirming 
good precision at low level of the developed analytical method.  
Accuracy 
The accuracy of an analytical procedure expresses the closeness of 
agreement between the value, which is accepted either as a 
conventional true value or an accepted reference value and the value 
found. The accuracy of the method was evaluated in triplicate at 
LOQ, 80% level (0.08µg/mL), 100% level (0.1µg/mL) and 120% 
level (0.12µg/mL). The percentage recovery of all impurities in drug 
substance has been calculated. Chromatogram of carvedilol spiked 
with five impurities was depicted in Figure 3. 
Robustness 
To evaluate the robustness of the developed method, the 
chromatographic conditions were deliberately altered and the 
resolution between closely eluting peaks that is, Imp-1 and Imp-2 
was evaluated. Close observation of analysis results of deliberately 
changed chromatographic conditions viz; flow rate (0.5±0.05 
mL/min), Mobile phase composition (± 2% acetonitrile) and column 
temperature (60±5 °C) revealed that resolution between Imp-1 and 
Imp-2 was greater than 2.0 and no significant change in relative 
retention time for all impurities in spiked sample illustrating the 
robustness of the method. 
Solution stability and mobile phase stability 
The solution stability of carvedilol and its related impurities was 
carried out by leaving both spiked and unspiked sample solutions in 
tightly capped UPLC vials at 25 °C for 48 h in an auto sampler. 
Content of each impurity was determined against freshly prepared 
standard solution. No significant changes were observed in the 
Sajan et al. 




content of any of the impurities. The solution stability and mobile 
phase stability experiment data confirms that the sample solutions 
and mobile phases used during related substance determination 
were stable for at least 48 hour. 
 
 
Fig. 4: (a) Typical chromatogram of carvedilol under stress conditions: (a) thermal degradation, (b) photolytic degradation, (c) acid 
hydrolysis,(d) oxidative degradation, (e) base hydrolysis and (f) in water 
 
CONCLUSION 
In this paper, a sensitive, selective, specific, accurate, validated and 
well-defined stability indicating UPLC method for the quantification 
of carvedilol process related impurities and degradation products 
were described. The major oxidative degradant was identified as 
carvedilol hydroxylamine. Detection limit for impurities was found 
to be as low as 0.002% and was found to have excellent resolution 
between impurities and carvedilol. This newly developed method 
has been validated as per regulatory requirements and can be used 
for routine and stability studies for the quantitative determination of 
potential impurities in carvedilol drug substance. 
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